Covx Technology Ireland, Ltd.

Covx Technologies Ireland Limited

Pfizer Healthcare Ireland

Abhijit Suresh Bhat

Curt William Bradshaw

Venkata Ramana Doppalapudi

Dingguo Liu

Jing-Yu Lai

Bin Liu

Gang Chen

Joel Desharnais

Yanwen Fu

David Tumelty

Alice Lee

Olivier Alexandre Laurent

Bryan Douglas Oates

Richard Ryan Preston

Wei Hong Yu

Anna Maria Tempczyk-Russell

Jing Yu Lai

Lauren Diane Wood

Anna Tempczyk-russell

The present invention relates to a polypeptide comprising 7 &#x3b2;-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first &#x3b1;-helix sequentially located on the EF chain between &#x3b2;-strands E and F, wherein the &#x3b2;-strands are arranged so as to form a first &#x3b2;-sheet comprising &#x3b2;-strands A, B, D, and E, and a second &#x3b2;-sheet comprising &#x3b2;-strands C, F and G, said first and second &#x3b2;-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between &#x3b2;-strands E and F comprises the sequence X-X-X-X-KH(SEQ ID NO:98), and X, Xand Xare each independently any amino acid residue, characterized in that Xis selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.

Mutant antibodies and conjugation thereof

The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Anti-angiogenic compounds

The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.

Methods of treating a disease or condition associated with abnormal angiogenesis

The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL&#x3ba;) comprising Kaccording to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Multifunctional antibody conjugates

The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Growing community of inventors

Encinitas, CA, United States of America

Abhijit Suresh Bhat